Key result
Four small molecule derivatives of WP1130 significantly reduced murine norovirus infection by 1.9 to 2.6 logs in vitro while exhibiting increased aqueous solubility and no significant cytotoxicity.
Chemical derivatives of the deubiquitinase inhibitor WP1130 maintain broad-spectrum antiviral activity against RNA viruses with improved aqueous solubility and no significant cytotoxicity in vitro.
Answers are grounded in this paper and cite their sources.
May support host-targeted antivirals for mutable RNA viruses; leaves open clinical translation pending in vivo data.
Most antiviral treatment options target the invading pathogen and unavoidably encounter loss of efficacy as the pathogen mutates to overcome replication restrictions. A good strategy for circumventing drug resistance, or for pathogens without treatment options, is to target host cell proteins that are utilized by viruses during infection. The small molecule WP1130 is a selective deubiquitinase inhibitor shown previously to successfully reduce replication of noroviruses and some other RNA viruses. In this study, we screened a library of 31 small molecule derivatives of WP1130 to identify compounds that retained the broad-spectrum antiviral activity of the parent compound in vitro but exhibited improved drug-like properties, particularly increased aqueous solubility. Seventeen compounds significantly reduced murine norovirus infection in murine macrophage RAW 264.7 cells, with four causing decreases in viral titers that were similar or slightly better than WP1130 (1.9 to 2.6 log scale). Antiviral activity was observed following pre-treatment and up to 1 hour postinfection in RAW 264.7 cells as well as in primary bone marrow-derived macrophages. Treatment of the human norovirus replicon system cell line with the same four compounds also decreased levels of Norwalk virus RNA. No significant cytotoxicity was observed at the working concentration of 5 µM for all compounds tested. In addition, the WP1130 derivatives maintained their broad-spectrum antiviral activity against other RNA viruses, Sindbis virus, LaCrosse virus, encephalomyocarditis virus, and Tulane virus. Thus, altering structural characteristics of WP1130 can maintain effective broad-spectrum antiviral activity while increasing aqueous solubility.
No takes yet. Share an insight, caveat, or question.
Gonzalez-Hernandez et al. (2014) studied RNA virus infection. WP1130 derivatives vs. DMSO vehicle control was evaluated on Viral titers (1.9 to 2.6 log decrease, p=<0.01). Four small molecule derivatives of WP1130 significantly reduced murine norovirus infection by 1.9 to 2.6 logs in vitro while exhibiting increased aqueous solubility and no significant cytotoxicity.
Synapse has enriched 10 related papers. Consider them for comparative context: